Cite
MLA Citation
A. Oaknin et al.. “Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC).” European journal of cancer, vol. 72, n.d., pp. S95–. http://access.bl.uk/ark:/81055/vdc_100041522201.0x00002d